Cna Financial Corp Coherus Bio Sciences, Inc. Transaction History

Cna Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$7.17 - $13.87 $3,656 - $7,073	-510 Reduced 1.76%	28,451 $273,000
Q2 2022 Aug 09, 2022	SELL	$5.86 - $13.23 $1,347 - $3,042	-230 Reduced 0.79%	28,961 $210,000
Q1 2022 May 10, 2022	SELL	$10.92 - $16.41 $1,201 - $1,805	-110 Reduced 0.38%	29,191 $377,000
Q4 2021 Feb 11, 2022	BUY	$15.81 - $18.99 $49,643 - $59,628	3,140 Added 12.0%	29,301 $468,000
Q3 2021 Nov 12, 2021	BUY	$12.68 - $17.79 $13,694 - $19,213	1,080 Added 4.31%	26,161 $420,000
Q2 2021 Aug 12, 2021	BUY	$12.95 - $15.41 $1,813 - $2,157	140 Added 0.56%	25,081 $347,000
Q1 2021 May 14, 2021	SELL	$14.42 - $21.39 $46,129 - $68,426	-3,199 Reduced 11.37%	24,941 $364,000
Q4 2020 Feb 12, 2021	BUY	$16.56 - $18.94 $53,819 - $61,555	3,250 Added 13.06%	28,140 $489,000
Q3 2020 Nov 12, 2020	BUY	$17.41 - $19.89 $48,922 - $55,890	2,810 Added 12.73%	24,890 $456,000
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $318,614 - $423,052	22,080 New	22,080 $394,000

136

78M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $86.3M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.